Eisai Launches ARICEPT, an Alzheimer's Disease Treatment in Asia
Tokyo (June 22, 1998) - Eisai Co., Ltd. of Tokyo (President and CEO:Haruo Naito) announced the launch of ARICEPT, (generic name: donepezil hydrochloride) a once daily symptomatic treatment for mild to moderate Alzheimer's disease by Eisai's subsidiaries in Thailand and Hong Kong.
In Asia marketing applications for ARICEPT were completed by March 1998 in Korea, China, the Philippines, Singapore, Malaysia, Indonesia, Taiwan and in other countries. At this time marketing approval has been received in Thailand and in Hong Kong and product launches will occur in each country as marketing authorizations are granted.
As of the end of March 1998, ARICEPT had been approved in 32 countries and launched in 21 countries. Eisai launched ARICEPT in 1997 in the U.S., the U.K., and Germany and in 1998 in France. ARICEPT is in the Phase III clinical trial stage in Japan.
ARICEPT inhibits acetylcholinesterase, an enzyme which breaks down the neurotransmitter acetylcholine, associated with memory and learning, thereby allowing a greater concentration of acetylcholine in the brain. ARICEPT is expected to improve cognition and patient function in people with mild to moderate Alzheimer's disease.
Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The company reported sales of about $2.3 billion in 1997 with approximately 16 percent of sales spent for research and development.
ARICEPT is a trademark of Eisai Co., Ltd.